Low-dose metronomic chemotherapy: A systematic literature analysis

Kerbel, 2004, The anti-angiogenic basis of metronomic chemotherapy, Nat Rev Cancer, 4, 423, 10.1038/nrc1369 Hanahan, 2000, Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice, J Clin Invest, 105, 1045, 10.1172/JCI9872 Browder, 2000, Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer, Cancer Res, 60, 1878 Klement, 2000, Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity, J Clin Invest, 105, R15, 10.1172/JCI8829 Pasquier, 2010, Metronomic chemotherapy: new rationale for new directions, Nat Rev Clin Oncol, 7, 455, 10.1038/nrclinonc.2010.82 Emmenegger, 2010, Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer, Recent Results Cancer Res, 180, 165, 10.1007/978-3-540-78281-0_10 Folkins, 2007, Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors, Cancer Res, 67, 3560, 10.1158/0008-5472.CAN-06-4238 Martin-Padura, 2012, Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts, Lab Invest, 92, 952, 10.1038/labinvest.2012.65 Mross, 2012, Metronomic anti-cancer therapy – an ongoing treatment option for advanced cancer patients, J Cancer Ther Res, 1, 32, 10.7243/2049-7962-1-32 Fontana, 2010, Metronomic chemotherapy for metastatic prostate cancer: a ‘young’ concept for old patients?, Drugs Aging, 27, 689, 10.2165/11537480-000000000-00000 Bocci, 2005, Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation, Ann Oncol, 16, 1243, 10.1093/annonc/mdi240 Collova, 2011, Use of metronomic chemotherapy in oncology: results from a national Italian survey, Tumori, 97, 454, 10.1177/030089161109700407 Kato, 2004, A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung, N Engl J Med., 350, 1713, 10.1056/NEJMoa032792 Watanabe, 2009, Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: national surgical adjuvant study for breast cancer 01 trial, J Clin Oncol, 27, 1368, 10.1200/JCO.2008.18.3939 Kerbel, 2012, Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer, J Mammary Gland Biol Neoplasia, 17, 229, 10.1007/s10911-012-9266-0 Maraveyas, 2005, Can a rational design for metronomic chemotherapy dosing be devised?, Br J Cancer, 92, 1588, 10.1038/sj.bjc.6602474 Green, 1980, Measurement of drug dosage intensity in MVPP therapy in Hodgkin’s disease, Br J Clin Pharmacol, 9, 511, 10.1111/j.1365-2125.1980.tb05847.x Dooley, 2004, Implications of dose rounding of chemotherapy to the nearest vial size, Support Care Cancer, 12, 653 Sacco, 2010, The average body surface area of adult cancer patients in the UK: a multicentre retrospective study, PLoS One, 5, e8933, 10.1371/journal.pone.0008933 Bank, 2012 Chabner, 2005, Timeline: chemotherapy and the war on cancer, Nat Rev Cancer, 5, 65, 10.1038/nrc1529 Miller, 2001, Redefining the target: chemotherapeutics as antiangiogenics, J Clin Oncol, 19, 1195, 10.1200/JCO.2001.19.4.1195 Vogelzang, 1984, Continuous infusion chemotherapy: a critical review, J Clin Oncol, 2, 1289, 10.1200/JCO.1984.2.11.1289 Kamen, 2005, Metronomic therapy: it makes sense and is patient friendly, J Pediatr Hematol Oncol, 27, 571, 10.1097/01.mph.0000192148.90120.15 Sobrero, 1997, Fluorouracil in colorectal cancer – a tale of two drugs: implications for biochemical modulation, J Clin Oncol, 15, 368, 10.1200/JCO.1997.15.1.368 Hahnfeldt, 2003, Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis, J Theor Biol, 220, 545, 10.1006/jtbi.2003.3162 Shaked, 2005, Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity, Blood, 106, 3058, 10.1182/blood-2005-04-1422 Bertolini, 2007, Molecular and cellular biomarkers for angiogenesis in clinical oncology, Drug Discov Today, 12, 806, 10.1016/j.drudis.2007.08.011 Takahashi, 2005, A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer, Pancreas, 30, 206, 10.1097/01.mpa.0000153335.73352.c7 Zhu, 2007, Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis, Am J Kidney Dis, 49, 186, 10.1053/j.ajkd.2006.11.039 Ederhy, 2011, Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists, Crit Rev Oncol Hematol, 80, 369, 10.1016/j.critrevonc.2011.01.009 des Guetz, 2011, Cardiovascular toxicity of anti-angiogenic drugs, Target Oncol, 6, 197, 10.1007/s11523-011-0204-7 Ivy, 2009, An overview of small-molecule inhibitors of VEGFR signaling, Nat Rev Clin Oncol, 6, 569, 10.1038/nrclinonc.2009.130 Ranpura, 2011, Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis, JAMA, 305, 487, 10.1001/jama.2011.51 Gardner, 2000, A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs, Cancer Res, 60, 1417 Perry, 2010, Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study, J Clin Oncol, 28, 2051, 10.1200/JCO.2009.26.5520 Meropol, 2009, American society of clinical oncology guidance statement: the cost of cancer care, J Clin Oncol, 27, 3868, 10.1200/JCO.2009.23.1183